IRIS
VERGARO, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.150
EU - Europa 7.688
AS - Asia 3.638
SA - Sud America 740
AF - Africa 50
Continente sconosciuto - Info sul continente non disponibili 22
OC - Oceania 7
Totale 23.295
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.670
RU - Federazione Russa 2.616
SG - Singapore 1.976
IT - Italia 1.773
GB - Regno Unito 1.068
DE - Germania 688
BR - Brasile 653
CN - Cina 573
HK - Hong Kong 424
CA - Canada 423
UA - Ucraina 417
IE - Irlanda 244
VN - Vietnam 235
SE - Svezia 172
FR - Francia 160
FI - Finlandia 152
DK - Danimarca 117
IN - India 71
NL - Olanda 65
AT - Austria 63
TR - Turchia 61
BD - Bangladesh 46
PK - Pakistan 46
PL - Polonia 45
ID - Indonesia 35
AR - Argentina 32
MX - Messico 32
AE - Emirati Arabi Uniti 28
IQ - Iraq 27
ES - Italia 26
UZ - Uzbekistan 22
EU - Europa 21
ZA - Sudafrica 20
JP - Giappone 17
LT - Lituania 17
BE - Belgio 12
RO - Romania 12
MA - Marocco 11
VE - Venezuela 11
CO - Colombia 9
CH - Svizzera 8
EC - Ecuador 8
MC - Monaco 8
PE - Perù 8
AZ - Azerbaigian 7
CL - Cile 7
CZ - Repubblica Ceca 7
IR - Iran 7
PH - Filippine 7
SA - Arabia Saudita 7
UY - Uruguay 7
AM - Armenia 6
JO - Giordania 6
AU - Australia 5
CR - Costa Rica 4
HU - Ungheria 4
IL - Israele 4
JM - Giamaica 4
KE - Kenya 4
KZ - Kazakistan 4
TH - Thailandia 4
TW - Taiwan 4
DZ - Algeria 3
HN - Honduras 3
KR - Corea 3
NI - Nicaragua 3
OM - Oman 3
PA - Panama 3
SM - San Marino 3
TN - Tunisia 3
TT - Trinidad e Tobago 3
AO - Angola 2
BB - Barbados 2
BH - Bahrain 2
BO - Bolivia 2
GE - Georgia 2
GH - Ghana 2
GR - Grecia 2
LB - Libano 2
MY - Malesia 2
NP - Nepal 2
NZ - Nuova Zelanda 2
PS - Palestinian Territory 2
PY - Paraguay 2
SK - Slovacchia (Repubblica Slovacca) 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
DO - Repubblica Dominicana 1
EG - Egitto 1
ET - Etiopia 1
GD - Grenada 1
GT - Guatemala 1
GY - Guiana 1
IS - Islanda 1
KH - Cambogia 1
LK - Sri Lanka 1
Totale 23.290
Salva come PNG Salva come JPEG
Città #
Singapore 1.192
Chicago 1.149
Los Angeles 601
Southend 540
Salt Lake City 511
Chandler 443
Fairfield 411
Hong Kong 384
Beijing 362
San Mateo 329
Woodbridge 329
Ashburn 320
Tampa 293
Houston 289
Wilmington 276
Buffalo 270
Moscow 249
Seattle 249
Ann Arbor 243
Dublin 238
Cambridge 232
Falls Church 232
Elk Grove Village 220
The Dalles 204
Boardman 188
Jacksonville 183
Ottawa 182
Dearborn 162
Beauharnois 155
Portsmouth 153
Milan 147
Munich 141
Stevenage 141
Pisa 137
Dong Ket 115
Dallas 111
Sterling 111
Lawrence 106
Rome 105
Lancaster 103
Florence 82
New York 80
Santa Clara 77
Miami 66
Dulles 65
London 62
Brooklyn 57
Nuremberg 56
Frankfurt am Main 51
São Paulo 51
Helsinki 49
San Diego 47
Turku 47
Kansas City 43
Detroit 42
Fremont 39
Istanbul 39
Warsaw 37
Redwood City 36
Washington 34
Bologna 33
Lappeenranta 30
Padova 29
Phoenix 29
Genoa 28
Vienna 28
Montréal 27
Pittsburgh 27
Belo Horizonte 25
Assago 24
Lucca 24
Palermo 24
Las Vegas 22
Livorno 22
Shanghai 22
Naples 21
San Francisco 21
Bari 20
Central District 20
Tashkent 20
Toronto 20
Düsseldorf 19
Hangzhou 19
Turin 19
New Delhi 18
Montreal 17
Old Bridge 17
Rio de Janeiro 17
Amsterdam 15
Buti 15
Mexico City 15
Charlotte 14
Atlanta 13
Guangzhou 13
Hounslow 13
Norwalk 13
Brasília 12
Brussels 12
Curitiba 12
Islamabad 12
Totale 13.667
Salva come PNG Salva come JPEG
Nome #
Prognostic value of soluble ST2 in AL and TTR cardiac amyloidosis: a multicenter study 1.718
N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis 1.493
Cardiac remodelling - Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology 1.398
Valutazione delle caratteristiche analitiche e dei risultati clinici di un metodo in chemiluminescenza a cattura di microparticelle (CMIA) per il dosaggio della Galectina-3 sulla piattaforma ARCHITECT 609
Patient-reported outcome measures for transthyretin cardiac amyloidosis: the ITALY study 473
Measurement of myocardial amyloid deposition in systemic amyloidosis: insights from cardiovascular magnetic resonance imaging 249
Value of the HFA-PEFF and H2FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis 220
Markers of fibrosis, inflammation, and remodeling pathways in heart failure 212
Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure: A Meta-Analysis 206
Targeting Mitochondrial Dysfunction in Chronic Heart Failure: Current Evidence and Potential Approaches 194
Galectin-3 and myocardial fibrosis in nonischemic dilated cardiomyopathy 192
Breathing Not Properly in the oldest old. Is brain natriuretic peptide a poor test for the diagnosis of heart failure in the elderly? 188
Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure 187
CHADS2 and CHA2DS2-VASc scores to predict morbidity and mortality in heart failure patients candidates to cardiac resynchronization therapy 186
Clinical relevance of non-cardiac determinants of natriuretic peptide levels. 183
Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers 180
Update sui biomarcatori nello scompenso cardiaco. 177
Predicting readmissions after hospitalization for heart failure: Medical reasoning vs calculators 174
Inhibition of Galectin-3 Pathway Prevents Isoproterenol-Induced Left Ventricular Dysfunction and Fibrosis in Mice 173
[18F]-Florbetaben PET/CT for Differential Diagnosis Among Cardiac Immunoglobulin Light Chain, Transthyretin Amyloidosis, and Mimicking Conditions 171
A simple echocardiographic score to rule out cardiac amyloidosis 170
Refractory hyperaldosteronism in heart failure is associated with plasma renin activity and angiotensinogen polymorphism 168
Cardiac light-chain deposition disease relapsing in the transplanted heart 167
Biomarkers of activation of renin-angiotensin-aldosterone system in heart failure: how useful, how feasible? 166
Adrenergic activation in heart failure: blockade or rebalance? 163
Prognostic significance of myocardial extracellular volume fraction in nonischaemic dilated cardiomyopathy 163
Sex-related differences in chronic heart failure 162
Prognostic value of plasma Renin activity in heart failure. 160
Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure: An Individual Patient Data Meta-Analysis 159
Correction of procedural arterial pseudoaneurysms: Established and novel procedures 159
The search for efficient diagnostic and prognostic biomarkers of heart failure 153
Modern diagnostic and therapeutical approach to cardiac AL amyloidosis and neuroendocrine model of heart failure: lessons from a clinical case. 152
How to take arms against central apneas in heart failure 150
Cheyne-Stokes respiration related oscillations in cardiopulmonary hemodynamics in patients with heart failure 148
Admission high-sensitivity troponin T and NT-proBNP for outcome prediction in acute heart failure 141
Effect of Sex on Reverse Remodeling in Chronic Systolic Heart Failure 141
Are big data on myocardial infarction enough for small heart failure patients? Lessons from a national registry 137
Upright Cheyne-Stokes Respiration in Patients With Heart Failure 134
NT-proBNP prognostic value is maintained in elderly and very elderly patients with chronic systolic heart failure 130
Circulating levels and prognostic cut-offs of sST2, hs-cTnT, and NT-proBNP in women vs. men with chronic heart failure 128
Body mass index and outcomes in ischaemic versus non-ischaemic heart failure across the spectrum of ejection fraction 128
Sympathetic and renin-angiotensin-aldosterone system activation in heart failure with preserved, mid-range and reduced ejection fraction 125
Approach to the diagnosis and management of patients with cardiac amyloidosis. A consensus document by the Tuscan section of the Italian Association of Hospital Cardiologists (ANMCO) and the Tusco-Umbrian section of the Italian Society of Cardiology (SIC) 124
Screening the health status of people working in a university 123
A simple echocardiographic score to rule out cardiac amyloidosis 120
Heart, kidney and FGF23: Les liaisons dangereuses 120
Central And Obstructive Apneas in Heart Failure With Reduced, Mid-Range And Preserved Ejection Fraction. 120
High-sensitivity troponin T, NT-proBNP and glomerular filtration rate: A multimarker strategy for risk stratification in chronic heart failure 119
Biomarkers for the diagnosis and management of heart failure 116
Atrial amyloidosis: mechanisms and clinical manifestations 114
Cheyne-Stokes respiration and heart failure: pathophysiologicaland clinical implications 114
Classification of patients with cardiac amyloidosis using machine learning models on Italian electronic clinical health records 113
Contribution of the lung to the genesis of cheyne-stokes respiration in heart failure: Plant gain beyond chemoreflex gain and circulation time 112
Noncardiac Versus Cardiac Mortality in Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction 110
Renin profiling predicts neurohormonal response to sacubitril/valsartan 110
Multiparametric Echocardiography Scores for the Diagnosis of Cardiac Amyloidosis 109
Healthy hearts at hectic pace: From daily life stress to abnormal cardiomyocyte function and arrhythmias 109
Wild-type transthyretin cardiac amyloidosis is not rare in elderly subjects: the CATCH screening study 108
Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings 108
A mechanistic look at sacubitril/valsartan action. Unravelling magician's secrets 107
Management of complications of cardiac amyloidosis: 10 questions and answers 105
Cardiogenic shock and acute kidney injury: the rule rather than the exception 105
Central apnoeas and ticagrelor-related dyspnoea in patients with acute coronary syndrome 105
In Vivo Murine Models of Cardiotoxicity Due to Anticancer Drugs: Challenges and Opportunities for Clinical Translation 105
N-terminal fraction of pro-B-type natriuretic peptide versus clinical risk scores for prognostic stratification in chronic systolic heart failure 104
sST2 Predicts Outcome in Chronic Heart Failure Beyond NT−proBNP and High-Sensitivity Troponin T 104
Amyloid deposits and fibrosis on left ventricular endomyocardial biopsy correlate with extracellular volume in cardiac amyloidosis 103
Prognostic value of reverse remodelling criteria in heart failure with reduced or mid-range ejection fraction 102
Subclinical cardiac damage in cancer patients before chemotherapy 102
Eligibility for vericiguat in a real‐world, contemporary heart failure population 101
Role of Imaging in Cardiomyopathies 100
The IL-33/ST2 pathway, inflammation and atherosclerosis: Trigger and target? 100
Biomarkers for the diagnosis and management of heart failure: New frontiers 100
Patients with cardiac amyloidosis have a greater neurohormonal activation than those with non-amyloidotic heart failure 100
Sacubitril–valsartan treatment is associated with decrease in central apneas in patients with heart failure with reduced ejection fraction 99
Sex-related differences in chronic heart failure 99
The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction 98
Clinical and Prognostic Significance of sST2 in Heart Failure: JACC Review Topic of the Week 97
Molecular autopsy of sudden cardiac death in the genomics era 96
Epidemiological and clinical boundaries of heart failure with preserved ejection fraction 95
Left ventricular ejection fraction for risk stratification in chronic systolic heart failure 95
[18F]-florbetaben PET/CT is sensitive for cardiac AL amyloidosis 95
Therapies for cardiac light chain amyloidosis: An update 94
Wet is bad: Residual congestion predicts worse prognosis in acute heart failure 94
Diphosphonate single-photon emission computed tomography in cardiac transthyretin amyloidosis 94
Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation 94
Mineralocorticoid receptor antagonists for heart failure: a real-life observational study 92
Deep learning to diagnose cardiac amyloidosis from cardiovascular magnetic resonance 92
Biomarkers for the diagnosis and management of heart failure: Natriuretic peptides 92
Clinical and prognostic significance of central and obstructive apnoeas in patients with transthyretin cardiac amyloidosis 91
Revisiting the obesity paradox in heart failure: Per cent body fat as predictor of biomarkers and outcome 91
Quality of life and outcome in heart failure with preserved ejection fraction: When sex matters 90
Echocardiographic findings in subjects with an amyloidogenic apolipoprotein A1 pathogenic variant 89
Deep-learning-based cardiac amyloidosis classification from early acquired pet images 89
[Rationale and significance of the Italian Network for Cardiac Amyloidosis] 88
Disease features and management of cardiomyopathies in women 88
Valvular heart disease in patients with cardiac amyloidosis 86
Left ventricular ejection fraction and coronary artery disease in the era of precision medicine 86
Biomarkers of heart failure with preserved and reduced ejection fraction 85
Monoclonal antibodies and amyloid removal as a therapeutic strategy for cardiac amyloidosis 84
Totale 17.772
Salva come PNG Salva come JPEG
Categoria #
all - tutte 154.829
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 154.829
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.294 170 193 94 205 120 286 198 136 187 151 243 311
2021/20221.911 161 295 80 196 74 67 201 333 141 195 36 132
2022/20231.334 109 110 62 140 164 175 36 120 251 30 82 55
2023/20241.331 76 36 239 101 73 120 102 65 51 75 55 338
2024/202513.502 112 132 487 200 420 489 1.183 2.120 812 2.024 3.134 2.389
2025/2026735 735 0 0 0 0 0 0 0 0 0 0 0
Totale 23.556